 The inhaled form is used with a proprietary inhalation device supplied by the manufacturer.Patients use one ampule with inhalation solution a day, four times a day at least four hours apart.The oral form of treprostinil was approved by the FDA in December 2013 and is marketed as the trade name Orenitram.